RESUMO
INTRODUCTION: Arrhythmia treatments today take three different approaches. One uses electronic devices, such as electronic pacemakers or defibrillators, and this is regarded as life-saving in cases of bradyarrhythmias and ventricular fibrillation. Another is the ablation technique which eliminates abnormal pacemakers and/or conductive pathways by applying thermal or cryo-injury to pathological portions of the heart. The most classical one is the antiarrhythmic drugs, but are they effective and safe? AREAS COVERED: Recent development of the understanding of arrhythmias, cardiac ionic channels and antiarrhythmic drugs covered by papers mostly published after 2000 are discussed. EXPERT OPINION: The market size of the antiarrhythmic drugs is small, but various multichannel acting drugs may become candidates as antiarrhythmic drugs. As the cardiac ionic channels have become recognized as proteins, the molecular target for antiarrhythmic drugs has become apparent, but at the same time accurate data on clinical effectiveness and safety are required for drug approval; thus, few atrium selective drugs, such as IKur, IKACh and IKAde blocking drugs and amiodarone-like multichannel acting drugs are being developed.
Assuntos
Antiarrítmicos/uso terapêutico , Arritmias Cardíacas/tratamento farmacológico , Descoberta de Drogas/métodos , Animais , Antiarrítmicos/administração & dosagem , Antiarrítmicos/efeitos adversos , Arritmias Cardíacas/metabolismo , Descoberta de Drogas/economia , Ásia Oriental , Humanos , Canais Iônicos/metabolismo , Marketing de Serviços de SaúdeRESUMO
Safety pharmacologists from the Japanese pharmaceutical industries and contract laboratories made a database to evaluate drug effects on the QT interval in 2005. This QT PRODACT project was a prospective study of 12 QT-prolonging (positive) drugs and 10 non-prolonging (negative) drugs to evaluate the specificity and sensitivity of several in vivo and in vitro animal models: in vitro guinea pig papillary muscle action potential recordings and in vivo ECG recordings in unanesthetized or anesthetized beagle dogs, cynomolgus monkeys and miniature pigs. In guinea pig papillary muscle action potential recordings, positive drugs showed lengthening of the action potential duration (APD). By using a new measure to detect triangulation of the action potential configuration, an IKr blocking activity of drugs with Ca channel blocking action was detected. All in vivo studies showed a QT-prolonging effect of greater than 10% for the positive drugs. These in vivo models were useful to distinguish positive from negative drugs. The QT PRODACT project showed reliability and sensitivity of the experiments to detect positive drugs. The proarrhythmic effects of these positive drugs could not be detected even though, in some animal models (e.g., unanesthetized monkey), torsades de pointes (TdP)-type arrhythmias were shown by terfenadine. We compared in vivo arrhythmia models for proarrhythmia. The halothane-anesthetized open chest coronary occlusion-reperfusion canine model, the halothane-adrenaline arrhythmia model and the chronic AV block dog models seemed to be useful to detect the arrhythmogenic potential of QT-prolonging drugs.
Assuntos
Modelos Animais de Doenças , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Torsades de Pointes/induzido quimicamente , Animais , Bases de Dados Factuais , Avaliação Pré-Clínica de Medicamentos/métodos , Eletrocardiografia , Humanos , Síndrome do QT Longo/induzido quimicamente , Reprodutibilidade dos Testes , Testes de Toxicidade/métodosRESUMO
In vitro electrophysiological studies have shown that second-generation antipsychotic drugs risperidone and olanzapine inhibit rapidly activating delayed rectifier K(+) currents and prolong action potential duration of the isolated ventricular myocardium. In this study, we analyzed in vivo cardiohemodynamic and electrophysiological profiles of risperidone and olanzapine using the halothane-anesthetized canine model to clarify their proarrhythmic potential. A clinically relevant dose of risperidone (0.03 mg/kg, i.v.) did not affect the ventricular repolarization process, whereas the supra-therapeutic doses (0.3 and 3 mg/kg, i.v.) prolonged the duration of monophasic action potential of the ventricle. Furthermore, the terminal repolarization period, an index of extent of electrical vulnerability, was prolonged after the supra-therapeutic doses. In contrast, therapeutic to supra-therapeutic doses of olanzapine (0.03-3 mg/kg, i.v.) hardly affected the ventricular repolarization process. Therefore, more caution has to be paid on the use of risperidone than olanzapine for patients with risks of the elevated plasma concentration.
Assuntos
Antipsicóticos/efeitos adversos , Arritmias Cardíacas/induzido quimicamente , Risperidona/efeitos adversos , Potenciais de Ação/efeitos dos fármacos , Anestesia , Animais , Benzodiazepinas/efeitos adversos , Benzodiazepinas/sangue , Pressão Sanguínea/efeitos dos fármacos , Fascículo Atrioventricular/efeitos dos fármacos , Fascículo Atrioventricular/fisiologia , Débito Cardíaco , Estimulação Cardíaca Artificial , Cães , Eletrocardiografia/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Masculino , Olanzapina , Risperidona/sangue , Resistência Vascular/efeitos dos fármacos , Função Ventricular Esquerda/efeitos dos fármacosRESUMO
Chronic atrioventricular block dogs have been established as an in vivo model of drug-induced torsades de pointes arrhythmias. We compared the cardiovascular profile of the canine model with that of sham-operated animals using echocardiographic and haemodynamic methods. In the echocardiographic study, the larger diameters of the left atria, inferior vena cava and left ventricle in end-diastole in addition to greater fractional shortening, end-diastolic volume, stroke volume and ejection fraction were more often detected in the chronic atrioventricular block dogs than in the sham-operated animals. During haemodynamic examination, lower cardiac output and higher pulmonary capillary wedge pressure were detected in chronic atrioventricular block dogs more than in sham-operated animals; however, these changes were within the physiological limits, and the results suggest that the chronic atrioventricular block dogs have a pathophysiological profile of chronic compensated heart failure.
Assuntos
Bloqueio Cardíaco/fisiopatologia , Coração/fisiopatologia , Torsades de Pointes/fisiopatologia , Animais , Pressão Sanguínea , Débito Cardíaco , Modelos Animais de Doenças , Cães , Ecocardiografia , Eletrocardiografia , Feminino , Frequência Cardíaca , Masculino , Volume SistólicoRESUMO
Although a second-generation histamine H(1) blocker terfenadine induced torsades de pointes (TdP) arrhythmias in patients via the blockade of a rapid component of delayed rectifier K(+) current (I(Kr)), such action of terfenadine has not been detected in previous animal models. We analysed the potential of the canine persistent atrioventricular block heart, a new in vivo proarrhythmia model, to detect a torsadogenic effect of terfenadine of an oral dose of 3 or 30 mg kg(-1). The doses can provide therapeutic to supra-therapeutic plasma concentrations as an anti-histamine. In 2 weeks of bradycardiac heart model, there were no significant changes in any of the electrocardiogram parameters after the administration of both doses of terfenadine. In 4-6 weeks of bradycardiac heart model, the low dose of terfenadine hardly affected any of the electrocardiogram parameters except that it induced TdP in one out of six animals. The high dose significantly decreased the atrial rate and ventricular rate, prolonged the QT interval, and induced TdP in five out of six animals. Moreover, temporal variability of repolarization increased after the high-dose administration. These results suggest that long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect terfenadine-induced TdP.
Assuntos
Bradicardia/fisiopatologia , Eletrocardiografia/efeitos dos fármacos , Bloqueio Cardíaco/fisiopatologia , Coração/efeitos dos fármacos , Antagonistas dos Receptores Histamínicos H1/efeitos adversos , Terfenadina/efeitos adversos , Torsades de Pointes/induzido quimicamente , Animais , Nó Atrioventricular/cirurgia , Bradicardia/etiologia , Ablação por Cateter , Cães , Relação Dose-Resposta a Droga , Coração/fisiopatologia , Bloqueio Cardíaco/complicações , Síndrome do QT Longo/etiologia , Síndrome do QT Longo/fisiopatologia , Modelos Animais , Fatores de Tempo , Torsades de Pointes/fisiopatologiaRESUMO
The utility of halothane-anaesthetized guinea-pigs as an in vivo model for predicting the clinical potential of a drug to induce QT interval prolongation was assessed using the electrocardiogram and monophasic action potential (MAP) recordings with electrical ventricular pacing. Intravenous administration of D-sotalol (0.3 mg kg(-1)) and terfenadine (0.3 mg kg(-1)), blockers of a rapid component of delayed rectifier potassium currents, prolonged the QT interval by 32+/-7 and 23+/-6 ms, respectively, whereas chromanol 293B (1 mg kg(-1)), a blocker of a slow component of delayed rectifier potassium currents, lengthened it by 33+/-8 ms. The extent of the QT interval prolongation by these drugs was greater than those in previous reports using pentobarbital-anaesthetized guinea-pigs. The MAP duration at the control was shortened by decreasing the pacing cycle length from 400 to 200 ms, but the MAP duration at each cycle length was prolonged by D-sotalol. The formulas of Van de Water, Matsunaga, Fridericia and Bazett showed good correlation of the repolarization period when compared with the MAP duration at a pacing cycle length of 400 ms. The halothane-anaesthetized guinea-pig model may possess enough sensitivity to detect drug-induced QT interval prolongation, indicating that halothane anaesthesia can reduce the repolarization reserve of the heart in vivo.
Assuntos
Anestésicos Inalatórios/farmacologia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Halotano/farmacologia , Sistema de Condução Cardíaco/efeitos dos fármacos , Ventrículos do Coração/efeitos dos fármacos , Coração/efeitos dos fármacos , Síndrome do QT Longo/induzido quimicamente , Potenciais de Ação/efeitos dos fármacos , Antagonistas Adrenérgicos beta/administração & dosagem , Antagonistas Adrenérgicos beta/efeitos adversos , Algoritmos , Anestésicos Inalatórios/administração & dosagem , Animais , Cromanos/administração & dosagem , Cromanos/farmacologia , Canais de Potássio de Retificação Tardia/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos/métodos , Eletrocardiografia/efeitos dos fármacos , Cobaias , Halotano/administração & dosagem , Antagonistas dos Receptores Histamínicos H1/administração & dosagem , Antagonistas dos Receptores Histamínicos H1/efeitos adversos , Modelos Lineares , Masculino , Modelos Animais , Preparações Farmacêuticas/administração & dosagem , Bloqueadores dos Canais de Potássio/administração & dosagem , Bloqueadores dos Canais de Potássio/farmacologia , Reprodutibilidade dos Testes , Sotalol/administração & dosagem , Sotalol/efeitos adversos , Sulfonamidas/administração & dosagem , Sulfonamidas/farmacologia , Terfenadina/administração & dosagem , Terfenadina/efeitos adversos , Fatores de TempoRESUMO
The effects of halothane and pentobarbital on the cardiovascular system were compared using the in vivo canine models. The ventricular repolarization process was longer under the halothane-anesthesia than pentobarbital-anesthesia. Intravenous administration of a selective blocker of rapidly activating delayed rectifier K+ currents (I(Kr)) sematilide prolonged the ventricular repolarization period without affecting the intraventricular conduction under both anesthesia; however, the potency was about 1.5-folds greater under the halothane-anesthesia than pentobarbital-anesthesia. These results suggest that halothane can more effectively sensitize the heart to pharmacological I(Kr) blockade, resulting in the excessive QT interval prolongation. Thus, the halothane-anesthetized canine model can be useful for predicting the in vivo I(Kr) blocking property of new drugs.
Assuntos
Proteínas de Transporte de Cátions/antagonistas & inibidores , Halotano/farmacologia , Coração/efeitos dos fármacos , Canais de Potássio de Abertura Dependente da Tensão da Membrana/antagonistas & inibidores , Animais , Proteínas de Transporte de Cátions/fisiologia , Canais de Potássio de Retificação Tardia , Cães , Canais de Potássio Éter-A-Go-Go , Feminino , Coração/fisiologia , Masculino , Bloqueadores dos Canais de Potássio/farmacologia , Canais de Potássio de Abertura Dependente da Tensão da Membrana/fisiologiaRESUMO
SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline), a novel and selective inhibitor of Na+/Ca2+ exchanger, was investigated for its possible antiarrhythmic effects on arrhythmias of Ca2+ overload induced by coronary ligation/reperfusion and by digitalis in the dog. SEA0400 (1.0 mg/kg) did not change the hemodynamics but slightly prolonged the QRS duration (P<0.05). Pre-ischemic administration (10 min before coronary occlusion) of SEA0400 (1.0 mg/kg) and post-ischemic administration (1 min before reperfusion) of SEA0400 (0.3, 1.0 and 3.0 mg/kg) had no effects on the incidence of ventricular fibrillation induced by coronary ligation/reperfusion. On the other hand, SEA0400 (3.0 mg/kg) decreased the arrhythmic ratio in the digitalis arrhythmias (P<0.01). However, atrioventricular block and cardiac standstill were induced in two digitalized dogs. In conclusion, SEA0400 has no significant antiarrhythmic effect on arrhythmias induced by coronary ligation/reperfusion, but has an obvious suppressing effect on tachyarrhythmias induced by digitalis in in vivo canine models.
Assuntos
Compostos de Anilina/uso terapêutico , Arritmias Cardíacas/tratamento farmacológico , Éteres Fenílicos/uso terapêutico , Trocador de Sódio e Cálcio/antagonistas & inibidores , Compostos de Anilina/farmacologia , Animais , Antiarrítmicos/farmacologia , Antiarrítmicos/uso terapêutico , Arritmias Cardíacas/fisiopatologia , Cães , Relação Dose-Resposta a Droga , Feminino , Ventrículos do Coração/efeitos dos fármacos , Ventrículos do Coração/fisiopatologia , Éteres Fenílicos/farmacologia , Trocador de Sódio e Cálcio/fisiologiaRESUMO
A 12-year-old girl with occasional symptoms of chest discomfort was diagnosed with ventricular tachycardia on cardiac evaluation. No evidence of organic heart disease was apparent, but a laboratory evaluation revealed hypomagnesemia. Ventricular tachycardia disappeared after treatment with 200 mg/day of oral magnesium hydroxide, and no further chest discomfort was reported. In addition to routine cardiac evaluation for arrhythmia, serum magnesium levels should be checked in patients with suspected idiopathic benign ventricular tachycardia. Treatment with oral magnesium is a physiologic therapy and should be considered for patients with ventricular tachycardia due to hypomagnesemia.
Assuntos
Deficiência de Magnésio/complicações , Magnésio/administração & dosagem , Taquicardia Ventricular/tratamento farmacológico , Administração Oral , Criança , Feminino , Humanos , Magnésio/sangue , Taquicardia Ventricular/sangueRESUMO
The purpose of this study was to evaluate a telemetry system for examining QT evaluation in the conscious free-moving guinea pig using 10 reference compounds whose effects on human QT interval are well established: 8 positive references (bepridil, terfenadine, cisapride, haloperidol, pimozide, quinidine, E-4031 and thioridazine), and 2 negative references (propranolol and nifedipine). Pharmacokinetic experiments were also performed for the 8 positive references. Telemetry transmitters were implanted subcutaneously in male Hartley guinea pigs, and the RR and QT intervals were measured. All 8 positive references prolonged QTc (QTc = k x QT/RR(1/2)) 10% or more during the 60 min observation period. When the values of the QTc changes were plotted against the serum concentrations, the resulting curves exhibited an anticlockwise hysteresis loop for all 8 references. In guinea pigs treated with haloperidol, changes of the T-wave shape from positive to flat were observed. The 2 negative references did not prolong the QTc. These findings suggest that the present telemetry guinea pig model is useful for QT evaluation in the early stages of drug development, because of the small body size of guinea pigs and their action potential configuration, which is similar to that of humans.
Assuntos
Eletrocardiografia/métodos , Síndrome do QT Longo/fisiopatologia , Telemetria/métodos , Animais , Antiarrítmicos/administração & dosagem , Antiarrítmicos/sangue , Antiarrítmicos/farmacocinética , Antipsicóticos/administração & dosagem , Antipsicóticos/sangue , Antipsicóticos/farmacocinética , Bepridil/administração & dosagem , Bepridil/sangue , Bepridil/farmacocinética , Cisaprida/administração & dosagem , Cisaprida/sangue , Cisaprida/farmacocinética , Modelos Animais de Doenças , Cobaias , Haloperidol/administração & dosagem , Haloperidol/sangue , Haloperidol/farmacocinética , Coração/efeitos dos fármacos , Coração/fisiologia , Coração/fisiopatologia , Humanos , Injeções Intravenosas , Síndrome do QT Longo/induzido quimicamente , Síndrome do QT Longo/diagnóstico , Masculino , Nifedipino/administração & dosagem , Nifedipino/sangue , Nifedipino/farmacocinética , Pimozida/administração & dosagem , Pimozida/sangue , Pimozida/farmacocinética , Piperidinas/administração & dosagem , Piperidinas/sangue , Piperidinas/farmacocinética , Piridinas/administração & dosagem , Piridinas/sangue , Piridinas/farmacocinética , Quinidina/administração & dosagem , Quinidina/sangue , Quinidina/farmacocinética , Reprodutibilidade dos Testes , Terfenadina/administração & dosagem , Terfenadina/sangue , Terfenadina/farmacocinética , Tioridazina/administração & dosagem , Tioridazina/sangue , Tioridazina/farmacocinéticaRESUMO
Given a limited information regarding the difference of the sensitivity of surrogate markers of drug-induced torsades de pointes, including early afterdepolarization, ectopic beats, phase 3 repolarization and dispersion of ventricular repolarization, we simultaneously analyzed them in the halothane-anesthetized canine model (n=5). A non-specific IKr channel blocker sparfloxacin, which has been known to induce torsades de pointes in animals and clinical patients, prolonged the repolarization process in a dose-related and reverse use-dependent manner. No significant change was detected in any of the proarrhythmic markers except for the backward parallel shift of phase 3 repolarization in the cardiac cycle with the QT interval prolongation, which would be the most sensitive marker in predicting the potential arrhythmogenic property of sparfloxacin in the "non-remodeled" normal heart.
Assuntos
Coração/efeitos dos fármacos , Torsades de Pointes/induzido quimicamente , Torsades de Pointes/fisiopatologia , Potenciais de Ação/efeitos dos fármacos , Potenciais de Ação/fisiologia , Animais , Biomarcadores/metabolismo , Cães , Eletrocardiografia/efeitos dos fármacos , Feminino , Fluoroquinolonas/efeitos adversos , Fluoroquinolonas/toxicidade , Coração/fisiologia , Frequência Cardíaca/efeitos dos fármacos , Frequência Cardíaca/fisiologiaRESUMO
Potential utility of mexiletine for the treatment of sparfloxacin-induced long QT syndrome was assessed using the in vivo halothane-anesthetized canine model. At 30 min after the administration of a supratherapeutic dose of sparfloxacin (30 mg/kg, i.v.), the mean blood pressure and heart rate decreased, whereas repolarization process and effective refractory period of the ventricular muscle were significantly prolonged. Additional administration of a clinically recommended dose of mexiletine (3 mg/kg, i.v.) at this time point increased the mean blood pressure, suppressed ventricular contraction, delayed atrioventricular as well as intraventricular conduction, and shortened repolarization process and effective refractory period. The extent of abbreviation of the repolarization was more prominent than that of the refractoriness, indicating that mexiletine could decrease the electrical vulnerability of the heart during sparfloxacin overdose. Thus, mexiletine may become a promising pharmacological strategy against the drug-induced long QT syndrome.
Assuntos
Antiarrítmicos/uso terapêutico , Antibacterianos/efeitos adversos , Fluoroquinolonas/efeitos adversos , Síndrome do QT Longo/tratamento farmacológico , Mexiletina/uso terapêutico , Potenciais de Ação/efeitos dos fármacos , Animais , Pressão Sanguínea/efeitos dos fármacos , Fascículo Atrioventricular/efeitos dos fármacos , Fascículo Atrioventricular/fisiopatologia , Cromatografia Líquida de Alta Pressão , Modelos Animais de Doenças , Cães , Eletrocardiografia , Feminino , Frequência Cardíaca/efeitos dos fármacos , Injeções Intravenosas , Síndrome do QT Longo/induzido quimicamente , Síndrome do QT Longo/fisiopatologia , Período Refratário Eletrofisiológico/efeitos dos fármacos , Fatores de Tempo , Função Ventricular Esquerda/efeitos dos fármacosRESUMO
Y-27632, (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride monohydrate, is a selective Rho-associated kinase inhibitor, which has been suggested to possess multiple clinical applications based on the in vitro observations. Since information regarding in vivo cardiovascular effects of Y-27632 is still limited, we assessed them using the halothane-anesthetized, closed-chest canine model. Administration of Y-27632 in a dose of 0.01 mg/kg, i.v. significantly decreased total peripheral vascular resistance together with an increase of cardiac output without affecting other cardiovascular parameters. Moreover, additional administration of Y-27632 in a dose of 0.1 mg/kg, i.v. significantly decreased blood pressure and left ventricular end-diastolic pressure, increased the heart rate and cardiac contractility, enhanced atrioventricular conduction and shortened the repolarization process as well as the effective refractory period. These results indicate that Y-27632 exerts a potent arterio-venodilator action with cardiostimulatory effects possibly through the sympathetic reflex in the in vivo canine model.
Assuntos
Amidas/farmacologia , Anestésicos Inalatórios/farmacologia , Sistema Cardiovascular/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Halotano/farmacologia , Peptídeos e Proteínas de Sinalização Intracelular , Proteínas Serina-Treonina Quinases/antagonistas & inibidores , Piridinas/farmacologia , Animais , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/fisiologia , Sistema Cardiovascular/enzimologia , Proteínas de Transporte/farmacologia , Cães , Feminino , Frequência Cardíaca/efeitos dos fármacos , Frequência Cardíaca/fisiologia , Proteínas Serina-Treonina Quinases/metabolismo , Quinases Associadas a rhoRESUMO
The proarrhythmic effects of fluoroquinolone antibacterial agents, sitafloxacin, gatifloxacin and moxifloxacin, were compared using three in vivo models. In the halothane-anesthetized dogs (n=5), intravenous 10-min infusion of gatifloxacin and moxifloxacin (1-3 mg/kg) prolonged the ventricular effective refractory period and the repolarization period to a similar extent, whereas sitafloxacin (1-3 mg/kg) prolonged the former only. No significant change was detected in other cardiovascular parameters. In the chronic complete atrioventricular block dogs (n=4), oral administration of 100 mg/kg of gatifloxacin (2 of 4) and moxifloxacin (3 of 4) induced torsades de pointes, which was not observed by sitafloxacin. In the alpha-chloralose-anesthetized rabbits (n=5), intravenous 20-min infusion of 60 mg/kg of gatifloxacin induced torsades de pointes (1 of 5) in the presence of methoxamine infusion, which was not observed by sitafloxacin or moxifloxacin. Thus, the halothane-anesthetized model is suitable for assessing QT prolongation, whereas the chronic complete atrioventricular block model is sensitive for detecting torsadogenic action of drugs. The alpha-chloralose-anesthetized model is the simplest and least expensive method, but its sensitivity to detect proarrhythmic action may be less great.
Assuntos
Compostos Aza/efeitos adversos , Fluoroquinolonas/efeitos adversos , Síndrome do QT Longo/induzido quimicamente , Quinolinas/efeitos adversos , Administração Oral , Animais , Compostos Aza/administração & dosagem , Pressão Sanguínea/efeitos dos fármacos , Cloralose , Modelos Animais de Doenças , Cães , Eletrocardiografia , Feminino , Fluoroquinolonas/administração & dosagem , Gatifloxacina , Halotano , Bloqueio Cardíaco/etiologia , Bloqueio Cardíaco/fisiopatologia , Frequência Cardíaca/efeitos dos fármacos , Infusões Intravenosas , Síndrome do QT Longo/fisiopatologia , Masculino , Moxifloxacina , Quinolinas/administração & dosagem , Coelhos , Medição de Risco , Fatores de Tempo , Torsades de Pointes/induzido quimicamente , Torsades de Pointes/fisiopatologia , Função Ventricular Esquerda/efeitos dos fármacosRESUMO
The protective effects of Cl(-)/HCO(3)(-) exchange inhibitors, 4,4'-diisothiocyano-stilbene-2,2'-disulfonic acid (DIDS) and 4-acetamido-4'isothiocyanato-stilbene-2,2'-disulfonic acid (SITS), against reperfusion-induced arrhythmias were investigated in anesthetized rats. Rats were subjected to 5-min occlusion of the left coronary artery followed by 10-min reperfusion. All drugs were intravenously administered 5 min before the onset of occlusion. DIDS (75 mg/kg) reduced the incidence of ventricular fibrillation and mortality to 0%, whereas SITS (75 mg/kg) only decreased these parameters to 60%. DIDS simultaneously decreased the mean blood pressure and heart rate, and prolonged PQ and QRS intervals, whereas SITS produced a weaker effect on these parameters and no change in QRS interval. Mexiletine (5 mg/kg), which had been demonstrated to suppress the arrhythmias and reduce the heart rate and mean blood pressure in this model, was shown to prolong PQ and QRS intervals. Verapamil (0.5 mg/kg) or diltiazem (0.4 mg/kg) suppressed the arrhythmias, simultaneously decreasing the heart rate and mean blood pressure and prolonging PQ interval. The results indicate that the protective effect of DIDS on reperfusion arrhythmias in the anesthetized rats is unlikely to be attributed to the inhibitory action on Cl(-)/HCO(3)(-) exchange, but possibly mediated by its blocking effects on cardiac ion channels, such as Na(+) or Ca(2+) channels.
Assuntos
Arritmias Cardíacas/metabolismo , Arritmias Cardíacas/fisiopatologia , Antiportadores de Cloreto-Bicarbonato/fisiologia , Traumatismo por Reperfusão Miocárdica/metabolismo , Traumatismo por Reperfusão Miocárdica/fisiopatologia , Ácido 4,4'-Di-Isotiocianoestilbeno-2,2'-Dissulfônico/farmacologia , Ácido 4,4'-Di-Isotiocianoestilbeno-2,2'-Dissulfônico/uso terapêutico , Ácido 4-Acetamido-4'-isotiocianatostilbeno-2,2'-dissulfônico/farmacologia , Ácido 4-Acetamido-4'-isotiocianatostilbeno-2,2'-dissulfônico/uso terapêutico , Animais , Antiarrítmicos/farmacologia , Antiarrítmicos/uso terapêutico , Arritmias Cardíacas/tratamento farmacológico , Antiportadores de Cloreto-Bicarbonato/antagonistas & inibidores , Masculino , Traumatismo por Reperfusão Miocárdica/tratamento farmacológico , Ratos , Ratos Sprague-DawleyRESUMO
The effects of famotidine on the cardiac repolarization process were assessed using four different levels of test systems described in the draft stage guideline ICH S7B. A supratherapeutic concentration of famotidine (10(-5) M), which is >8 times higher than C(max) obtained after its therapeutic dose, neither inhibited human ether-a-go-go-related gene (HERG) K(+) current expressed in human embryonic kidney 293 (HEK293) cells nor affected any of the action potential parameters of guinea pig papillary muscles. Therapeutic (0.3 mg/kg, i.v.) to supratherapeutic doses (3-10 mg/kg, i.v.) of famotidine did not affect the repolarization process of the halothane-anesthetized canine model, while only supratherapeutic doses exerted the positive chronotropic, inotropic and dromotropic effects without affecting the mean blood pressure. Moreover, supratherapeutic doses of famotidine (1-10 mg/kg, i.v.) neither induced torsades de pointes nor prolonged QT interval in the canine chronic atrioventricular conduction block model. These results suggest that famotidine possesses no cardiovascular effects at a therapeutic dose, while it may exert cardiostimulatory actions after drug overdoses that might potentiate the proarrhythmic potential of co-administered cardiotonic agents by increasing the intracellular Ca(2+) concentration.
Assuntos
Proteínas de Transporte de Cátions , Proteínas de Ligação a DNA , Famotidina/efeitos adversos , Antagonistas dos Receptores H2 da Histamina/efeitos adversos , Síndrome do QT Longo/induzido quimicamente , Canais de Potássio de Abertura Dependente da Tensão da Membrana , Transativadores , Potenciais de Ação/efeitos dos fármacos , Animais , Linhagem Celular , Cães , Canal de Potássio ERG1 , Eletrocardiografia , Canais de Potássio Éter-A-Go-Go , Cobaias , Bloqueio Cardíaco/induzido quimicamente , Bloqueio Cardíaco/fisiopatologia , Hemodinâmica/efeitos dos fármacos , Antagonistas dos Receptores Histamínicos H1/farmacologia , Humanos , Técnicas In Vitro , Síndrome do QT Longo/fisiopatologia , Músculos Papilares/efeitos dos fármacos , Músculos Papilares/fisiologia , Técnicas de Patch-Clamp , Fenetilaminas/farmacologia , Bloqueadores dos Canais de Potássio/farmacologia , Canais de Potássio/efeitos dos fármacos , Sulfonamidas/farmacologia , Terfenadina/farmacologia , Torsades de Pointes/induzido quimicamente , Torsades de Pointes/fisiopatologia , Regulador Transcricional ERGRESUMO
G protein-coupled receptor (GPCR) subtypes are differentially distributed in the cell; however, it remains unclear how this affects the subtype selectivity of particular drugs. In the present study, we used flow cytometry analysis with the fluorescent ligand, BODIPY FL-prazosin, to study the relationship between the subcellular distribution of subtype receptors and the subtype-selective character of ligands using alpha1a and alpha1b-adrenoceptors (ARs). Alpha1a-ARs predominantly localize inside the cell, while alpha1b-ARs on the cell surface. Flow cytometry analysis and confocal laser-scanning micrographs of living cells showed that BODIPY FL-prazosin can label not only alpha1-ARs on the cell surface, but also those localized inside the cell. Furthermore, flow cytometry analysis of alpha1A-AR-selective drug, KMD-3213, and alpha1B-AR-selective drug, CEC, revealed that the major determinant of the subtype selectivity of each drug is different. The alpha1A-AR selectivity of KMD-3213 can be explained by its much higher affinity for alpha1a-AR than alpha1b-AR (affinity-dependent selectivity), while the alpha1B-AR selectivity of the hydrophilic alkylating agent CEC is due to preferential inactivation of alpha1-ARs on the cell surface (receptor localization-dependent selectivity). This study illustrates that factors in addition to the affinity of the drug for the receptor, such as subcellular localization of the receptor, should be taken into account in assessing the subtype selectivity of a drug.
Assuntos
Compostos de Boro/metabolismo , Clonidina/análogos & derivados , Corantes Fluorescentes/metabolismo , Receptores Adrenérgicos alfa 1/metabolismo , Antagonistas Adrenérgicos alfa/farmacologia , Animais , Compostos de Boro/química , Células COS/química , Células COS/efeitos dos fármacos , Clonidina/farmacologia , Citometria de Fluxo , Corantes Fluorescentes/química , Indóis/farmacologia , Ligantes , Microscopia Confocal , Prazosina/química , Receptores Adrenérgicos alfa 1/análise , Receptores Adrenérgicos alfa 1/classificação , Frações Subcelulares/química , TransfecçãoRESUMO
The purpose of this study was to evaluate a telemetry system for examining the cardiovascular system in the conscious common marmoset. Parameters obtained were blood pressure, heart rate, respiratory rate, ECG, body temperature and locomotor activity, and these were continuously recorded on a data recorder via the telemetry system and then processed by a computerized system. Diurnal rhythms of blood pressure, heart rate, body temperature and locomotor activity were observed in this system. We studied the effects of astemizole (antihistamine) and nicardipine (Ca2+ channel blocker) on cardiovascular parameters. Astemizole at 30 mg/kg (p.o.) and at 1 to 3 mg/kg (i.v.), prolonged QT interval and induced ventricular extrasystole. Torsades de pointes occurred in one of three cases at 3 mg/kg (i.v.) and 30 mg/kg (p.o.), while it did not affect the blood pressure, respiratory rate and body temperature. Nicardipine at 30 mg/kg (p.o.) caused sustained hypotension and tachycardia. These results demonstrate the usefulness of the telemetry system using the common marmoset for evaluating the cardiovascular effects of drugs under physiological conditions.
Assuntos
Antialérgicos/toxicidade , Astemizol/toxicidade , Bloqueadores dos Canais de Cálcio/toxicidade , Callithrix , Fenômenos Fisiológicos Cardiovasculares/efeitos dos fármacos , Nicardipino/toxicidade , Telemetria/veterinária , Animais , Ritmo Circadiano , Relação Dose-Resposta a Droga , Eletrocardiografia/efeitos dos fármacos , Eletrocardiografia/veterinária , Masculino , Telemetria/métodosRESUMO
The aim of this study was to classify antiarrhythmic drugs based on their effectiveness on 6 in vivo arrhythmia models, mainly using dogs. The models were produced by two-stage coronary ligation, digitalis, halothane-adrenaline, programmed electrical stimulation in old myocardial infarction dogs, coronary artery occlusion/reperfusion, or chronic atrioventricular block. Na(+)-channel-blocking drugs suppressed two-stage coronary ligation and digitalis arrhythmias. Ca(2+)-channel blockers and beta-blockers suppressed halothane-adrenaline arrhythmia. Positive inotropic drugs aggravated halothane-adrenaline arrhythmia, but did not aggravate digitalis arrhythmia. K(+)-channel blockers suppressed programmed electrical stimulation induced arrhythmia, but induced torsades de pointes type arrhythmia in chronic atrioventricular block dogs and aggravated halothane-adrenaline arrhythmia. Na(+)/H(+)-exchange blockers suppressed coronary artery occlusion/reperfusion arrhythmias. This classification may be useful for predicting the clinical effectiveness in the preclinical stage of drug development.
Assuntos
Antiarrítmicos/uso terapêutico , Arritmias Cardíacas/tratamento farmacológico , Pesquisa Biomédica/métodos , Modelos Biológicos , Animais , Antiarrítmicos/classificação , Arritmias Cardíacas/fisiopatologia , Pesquisa Biomédica/normas , Pesquisa Biomédica/tendências , HumanosRESUMO
We have reported that chronically administered pravastatin prevented coronary artery reperfusion-induced lethal ventricular fibrillation (VF) in anesthetized rats without lowering the serum cholesterol level. The present study was undertaken to evaluate whether pravastatin prevents ischemia-induced lethal VF, simultaneously examining myeloperoxidase (MPO) activity in ischemic myocardial tissues. Anesthetized rats were subjected to 30-min ischemia and 60-min reperfusion after chronic administration of pravastatin (0.02, 0.2, and 2 mg/kg), fluvastatin (2 and 4 mg/kg), or vehicle for 22 days, orally, once daily. ECG and blood pressure were continually recorded, and MPO was measured by a spectrophotometer. Pravastatin and fluvastatin significantly (P<0.05) decreased MPO activities, but only pravastatin decreased the incidence of ischemia-induced lethal VF. Both statins had no significant effects on body weight, blood pressure, heart rate, and QT interval as we reported earlier. Our results prove further that pravastatin has benefits to decrease cardiovascular mortality beyond its cholesterol-lowering effect. Pravastatin is more potent than fluvastatin in prevention of arrhythmias. A decrease in the neutrophil infiltration may be partly involved in the inhibitory effect of pravastatin on the ischemia-induced VF.